Led · Series A · Aug 2025

Ribopeutic is a China-based RNA therapeutics developer that combines artificial intelligence with laboratory validation to identify RNA structures targetable by small molecules. Founded in 2022 and emerging from stealth, the company is advancing its pipeline toward investigational new drug (IND) filings. Its programs target central nervous system disorders, cancer, and autoimmune conditions. Ribopeutic recently secured close to 100 million yuan (~$13.9M) in pre-A financing to push its lead programs forward. The funding is intended to support advancement of lead programs and to expand the company’s early-stage pipeline.

Led · Series A · Nov 2023

Lingbo Biotech is focused on developing and industrializing small‑diameter bioartificial blood vessel technology. Its core products are biologic small‑caliber vascular grafts intended for cardiac bypass, dialysis access and peripheral vascular applications. The company recently completed an A+ financing round of several tens of millions of RMB. Proceeds from the round will be used to advance clinical development of existing products and to develop a new coronary artery bypass graft indication. Lingbo intends to accelerate multiple preclinical research programs and to push forward R&D and innovation in the regenerative medicine field. Lingbo Bio develops small‑diameter bioartificial vascular grafts aimed at clinical use. The company seeks to industrialize small‑diameter bioartificial blood vessel technology for surgical and vascular-disease applications. Its products target patients needing coronary artery bypass grafting, hemodialysis access, and peripheral vascular procedures. The firm emphasizes translating bioengineered vascular solutions into commercial medical devices. The article notes a recent financing event indicating investor confidence to support further development and commercialization efforts. No operating metrics (revenue or user numbers) are disclosed in the article.

Led · Series A · Jun 2022

PPIO provides edge cloud computing services and solutions designed for low latency, high bandwidth, and large-scale distributed processing, serving clients with distributed computing demands across China. The company offers comprehensive capabilities including audio and video management, cloud security, and application performance optimization for customers such as long- and short-video platforms, live-streaming services, and phone manufacturers. PPIO reports deployments in more than 1,000 cities and regions across 30+ provinces in China. Founded in 2018 by Wang Wenyu and Yao Xin, the firm has collaborated with leading Internet companies, first-tier cloud providers and unicorn startups on edge cloud business. PPIO plans to use its latest funding to enhance proprietary technologies and edge infrastructure and to strengthen R&D for ultra-low-latency scenarios including ultra-low-latency live streaming, cloud gaming, cloud rendering, connected vehicles and space digitization. With growing industrial digitization and rising demand for edge solutions, the company positions itself to support time-sensitive, near-real-time processing at the network edge. PPIO began commercial monetization in 2020 and provides edge‑cloud services for low‑latency, high‑bandwidth, compute‑heavy scenarios. The company has deployed micro data centers and distributed compute resources in over 800 Chinese county‑level locations, enabling nationwide dynamic deployment of distributed IaaS and PaaS. It counts more than ten large internet companies, cloud vendors and unicorns as customers, supporting growing edge compute, storage and transmission needs. In 2021 the company’s first three quarters of revenue exceeded ¥100 million. Cumulative financing to date exceeds ¥300 million. PPIO is focused on continuing development of edge‑cloud native technology and expanding commercial deployments in audio‑video, cloud gaming, distributed cloud rendering and edge AI. The business was founded in 2018 by PPTV founder Yao Xin and chief architect Wang Wenyu.

Led · Equity · Jun 2022

NuProbe Global is a genomics and molecular diagnostics company with sites in Houston, TX, Shanghai, and Suzhou. The company develops molecular diagnostic technologies that improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe is led by CEO Yingshuang Chai and co-founder David Zhang, who is also CEO of NuProbe USA. The company raised $50M in funding to support its growth. Proceeds will be used to expand commercial operations, accelerate IVD product clinical studies and regulatory submissions, and develop new genomics and molecular diagnostics technologies. Since its last fundraising in 2021, NuProbe has engaged in research collaborations with several multinational companies and clinical collaborations with over 400 hospitals. NuProbe develops molecular diagnostic technologies and ultrasensitive NGS panels that it says improve detection of sequencing mutations and copy number variations by over 10-fold. The company has signed partnership and licensing deals with Illumina, Qiagen, Oxford Nanopore and the Wego Group, and has begun partnering with pharma companies for clinical research using its Augury™ custom NGS panels. In China’s reproductive health market NuProbe has built collaborations with most top hospitals and is described as a leader in infertility testing. Led by co-founder and CEO Yingshuang Chai, the team includes co-founder and Head of Innovation David Zhang and a scientific advisory board featuring David Walt and George Church. NuProbe operates out of Houston (USA), Shanghai and Suzhou (China). The company plans to expand its commercial teams in the US and China, develop new NGS products, and pursue regulatory approval in China for its clinical products. NuProbe develops toehold probe–based molecular diagnostics technology licensed from Harvard’s Wyss Institute and Rice University to enable highly sensitive, multiplexed detection of disease signatures in cell-free DNA. Its core product focus is on ultra-sensitive, non-invasive blood tests for early cancer detection, infectious disease, and other genomics applications, with platforms intended for cancer, NIPT, and infectious-disease diagnostics. In pre-clinical work the technology improved qPCR and NGS mutation detection sensitivity by 10–100×, achieving limits of detection down to 0.01% and demonstrating multiplexing of 10–100 reactions capable of detecting hundreds of mutations. The proprietary assays are compatible with common PCR and sequencing workflows, which the company says supports clinical applicability. NuProbe plans to use new funding to grow staff in its Cambridge, Mass. and China offices and to continue technology development, clinical trials, and commercialization efforts. Financially, the company recently completed an $11 million Series A to support these development and go-to-market activities.

Participated · Series C · Jan 2022

GenFleet Therapeutics is a clinical-stage biotechnology company based in Shanghai focused on developing cutting-edge therapies in oncology and immunology. The company has a proprietary R&D and discovery platform and is developing both small molecules and biologics. Its diversified pipeline includes over 10 products, many of which have progressed into clinical stages. GenFleet is expanding clinical trials in China, the United States and Australia and expects more programs to move into late-stage clinical development in 2022. Management says proceeds will support global development of clinical-stage programs, build a broader portfolio of innovative programs, and accelerate commercialization over the coming years. GenFleet Therapeutics develops new drug candidates and is stepping into global multi-center clinical trials. The company announced a Series B+ financing in the hundreds of millions of RMB to speed development of its existing products and the conduct of its clinical trials. It plans to create an international cutting‑edge R&D system and open its industrial layout in parallel. Proceeds will be used to continually complete milestones of its "global new" drug development. The financing marks a new development stage focused on accelerating clinical programs and building international capabilities. DeHeng Law Offices acted as legal counsel on the transaction. GenFleet Therapeutics develops small-molecule therapeutics for immuno-oncology. The company’s first product entered IND application stage just over one year after the program was launched. Proceeds from its latest financing are intended to advance the IND application and subsequent clinical development of that program. GenFleet says it is executing projects rapidly and expanding its pipeline and business functions. Leadership has stated the company aims to become a pioneer in immuno-oncology and to build an innovative, balanced product portfolio to address unmet needs. The company is based in Shanghai, China.